MADRID, Dec. 26 (EUROPA PRESS) –
Scientists from Northwestern Medicine (USA) have discovered two therapies that, tested in mice, manage to delay the progression of pediatric leukemia, and now they hope to combine them into "super drugs" and will test it in people within the clinical trial .
Although there are several types of leukemia, this study, published in three studies in the last two years in Cell magazine, and in the latest article on Genes and Development, focused on the two most common findings found in infants through adolescents: acute myeloid leukemia AML) and acute lymphocytic leukemia (ALL).
Over the past 25 years, the Shilatifard Laboratory has been studying the molecular function of a key leukemia protein called MLL within its complex known as Compass (complexes linked to Set1), which is seen to be from mutations identified most commonly in cancer.
"I have been working on this translocation for more than two decades, and finally we are in a place where, in five to ten years, we can get remedies for children that can be effective if we can increase that survival rate by 85 percent. , it's a great achievement, "the researchers said.